CD33 and acute myeloid leukemia: Two ATACs are currently in clinical testing with no published results yet: the anti-CD33/CD3 GEM333 for r/r AML (NCT03516760), and the anti-PSCA/CD3 GEM3PSCA for various advanced solid tumors (NCT03927573).